Allogeneic bone marrow transplantation in the treatment of hematologic diseases
- PMID: 3886273
Allogeneic bone marrow transplantation in the treatment of hematologic diseases
Abstract
The current use of allogeneic bone marrow transplantation in various hematologic diseases is reviewed. Bone marrow transplantation (BMT) involves infusion of bone marrow from a suitable donor into a properly conditioned recipient. Most BMT is allogeneic, in which the donor is genetically dissimilar but shares some common tissue antigens with the recipient. Almost all patients undergoing allogeneic BMT must be "prepared" with high-dose cyclophosphamide to prevent graft rejection. Most patients with hematologic malignancy also receive total body irradiation to eradicate malignant cells located in areas inaccessible to the systemic circulation. Bone marrow transplantation is the treatment of choice for severe aplastic anemia. In acute myelogenous leukemia, the best results are observed in young patients undergoing BMT in first remission. In acute lymphoblastic leukemia, BMT is usually reserved for patients in second or subsequent remission. Early results are promising in patients with chronic myelogenous leukemia who receive BMT before the accelerated phase or blast crisis of this disease. Allogeneic BMT offers an opportunity for cure in some patients with relapses of Hodgkin's disease or those with certain subtypes of non-Hodgkin's lymphoma. Other diseases for which BMT has been used include severe combined immune deficiency disease, Fanconi's anemia, and multiple myeloma. Complications of BMT include graft failure or rejection, acute and chronic graft-versus-host disease, and infectious complications; late complications, such as restrictive and obstructive pulmonary disease, cataracts, sterility, and secondary malignancies, may also occur. Bone marrow transplantation has become an important treatment for many hematologic diseases, but it will probably remain a treatment reserved for only a few highly specialized centers. If morbidity and mortality caused by transplant-related complications can be reduced, BMT may be offered to older patients and those without HLA-identical sibling donors.
Similar articles
-
Marrow transplantation: the Seattle experience.Tokai J Exp Clin Med. 1985 Jun;10(2-3):75-83. Tokai J Exp Clin Med. 1985. PMID: 3914747
-
Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.Exp Hematol. 1995 Dec;23(14):1553-62. Exp Hematol. 1995. PMID: 8542946
-
[Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].Wien Klin Wochenschr. 1994;106(7):201-7. Wien Klin Wochenschr. 1994. PMID: 8197754 German.
-
[Indications, technique and risks in bone marrow transplantation in adulthood].Praxis (Bern 1994). 1996 Mar 19;85(12):378-86. Praxis (Bern 1994). 1996. PMID: 8643901 Review. German.
-
Allogeneic bone marrow transplantation.Crit Rev Clin Lab Sci. 1983;19(3):173-86. doi: 10.3109/10408368309165762. Crit Rev Clin Lab Sci. 1983. PMID: 6373140 Review.
Cited by
-
A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia.Cells. 2021 Oct 21;10(11):2833. doi: 10.3390/cells10112833. Cells. 2021. PMID: 34831055 Free PMC article. Review.
-
The association between genetic variants at 3'-UTR and 5'-URR of HLA-G gene and the clinical outcomes of patients with leukemia receiving hematopoietic stem cell transplantation.Front Immunol. 2023 Feb 23;14:1093514. doi: 10.3389/fimmu.2023.1093514. eCollection 2023. Front Immunol. 2023. PMID: 36911734 Free PMC article.
-
Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults.Curr Opin Oncol. 2012 Mar;24(2):182-90. doi: 10.1097/CCO.0b013e32834f5c41. Curr Opin Oncol. 2012. PMID: 22234252 Free PMC article. Review.
-
The adverse events of haematopoietic stem cell transplantation are associated with gene polymorphism within human leukocyte antigen region.Sci Rep. 2021 Jan 14;11(1):1475. doi: 10.1038/s41598-020-79369-w. Sci Rep. 2021. PMID: 33446692 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials